C
Christine Dela Cruz
Researcher at Bristol-Myers Squibb
Publications - 17
Citations - 4101
Christine Dela Cruz is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Sorafenib. The author has an hindex of 12, co-authored 15 publications receiving 2980 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Masatoshi Kudo,Guohong Han,Richard S. Finn,Ronnie T.P. Poon,Jean-Frédéric Blanc,Lunan Yan,Jijin Yang,Ligong Lu,Won Young Tak,Xiaoping Yu,Joon-Hyeok Lee,Shi-Ming Lin,Changping Wu,Tawesak Tanwandee,Guoliang Shao,Ian Walters,Christine Dela Cruz,Valerie Poulart,Jianhua Wang +18 more
TL;DR: In this study, brivanib as adjuvant therapy to TACE did not improve OS and the trial was terminated after randomization of 502 patients when two other phase III studies of Brivanib in advanced HCC patients failed to meet OS objectives.
Journal ArticleDOI
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
Anthony B. El-Khoueiry,Ignacio Melero,Todd S. Crocenzi,Theodore H. Welling,Thomas Yau,Winnie Yeo,Akhil Chopra,Joseph F. Grosso,Lixin Lang,Jeffrey Anderson,Christine Dela Cruz,Bruno Sangro +11 more
TL;DR: Nivolumab has a manageable AE profile and produced durable responses across all dose levels and HCC cohorts, with a favorable 6-month OS rate.
Journal ArticleDOI
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau,Yoon-Koo Kang,Tae-You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming-Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Aiwu Ruth He,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Jaclyn Neely,Yun Shen,Carlos Baccan,Christine Dela Cruz,Chiun Hsu +19 more
TL;DR: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% a...
Journal ArticleDOI
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau,Chiun Hsu,Tae You Kim,Su Pin Choo,Yoon-Koo Kang,Ming-Mo Hou,Kazushi Numata,Winnie Yeo,Akhil Chopra,Masafumi Ikeda,Ryoko Kuromatsu,Michihisa Moriguchi,Yee Chao,Huanyu Zhao,Jeffrey Anderson,Christine Dela Cruz,Masatoshi Kudo +16 more
TL;DR: The CheckMate 040 study as mentioned in this paper evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy.